Immunotherapy News and Research

Latest Immunotherapy News and Research

TopoTarget pays Celldex Therapeutics $3M sublicense income over Belinostat co-development agreement

Celldex Therapeutics, Inc. today announced that it has received a sublicense income payment of $3 million from TopoTarget A/S as a result of the recent co-development and commercialization agreement between TopoTarget and Spectrum Pharmaceuticals, Inc. for Belinostat, a novel histone deacetylase (HDAC) inhibitor for the treatment of cancer.

17 Feb 2010

Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency

Octapharma AG today announced the start of the first of a series of Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIG). The study will investigate the efficacy and safety of this novel immunoglobulin in the treatment of primary immune deficiency and, together with results from additional upcoming studies, will support its regulatory filing in Europe and the US.

16 Feb 2010

People can take simple steps to minimize risk of exposure to allergens during gardening, AAAAI

The beauty of budding plants and bouquet of aromas are sources of satisfaction for many gardeners. For allergy sufferers, though, gardening can be as much a chore as pursuit of passion.

15 Feb 2010

Ragweed pollen allergy: SLIT safe and effective alternative to injections

An oral allergy treatment administered in drops under the tongue is a safe and effective alternative to injections for adults who are allergic to ragweed pollen, according to a study published today in the Journal of Allergy and Clinical Immunology by allergic disease specialist at Allegheny General Hospital.

15 Feb 2010

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia's latest clinical results follow two earlier successful phase II studies with the company's T-cell vaccine against cat allergy.

12 Feb 2010

NewLink Genetics receives FDA SPA approval for HyperAcute immunotherapy Phase 3 pancreatic cancer trial

NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer. Pancreatic cancer is highly lethal and is currently an area of very significant unmet medical need. The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of a Phase 3 trial to be used in support of a Biologic License Application (BLA).

12 Feb 2010

Intellect Neurosciences: Several significant stakeholders commit funds

Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease ("AD"), announced today that several of its significant shareholders (the "Interested Shareholders") have agreed in principle to provide interim funding to the Company and assist the Company in its efforts to restructure its balance sheet.

11 Feb 2010

LRF's 2009 Mantle Cell Lymphoma Consortium report published

Highlights from the Lymphoma Research Foundation (LRF) 2009 Mantle Cell Lymphoma Consortium (MCLC) Scientific Workshop will be published in the March 2010 issue of Leukemia & Lymphoma. Traditionally accessible to subscribers for period of one year, Leukemia and Lymphoma has agreed to make this report available to the public for one month -- Mantle Cell Lymphoma: Report of the 2009 MCL Consortium Workshop.

10 Feb 2010

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Elan Corporation, plc today reported its fourth quarter and full-year 2009 financial results and provides financial guidance for 2010.

10 Feb 2010

Advaxi to receive fund from CRUK for clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis’ lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.

10 Feb 2010

Market Media Connect retained as Northwest Biotherapeutics' communications agency of record

Northwest Biotherapeutics, Inc., a development stage biotechnology company focused on personalized cancer vaccines to enhance immune system responses to tumors, has retained Market Media Connect as their communications agency of record. Led from its Los Angeles headquarters, Market Media Connect will support Northwest's communication objectives as the company moves into the next phase of its development.

8 Feb 2010

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Pfizer Inc. and DxS (a wholly owned subsidiary of QIAGEN N.V.) today announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM).

5 Feb 2010

HST Global plans to develop new Clinical Treatment Facility in Ecuador

HST Global, Inc. today announced that it has targeted Ecuador for development of a Clinical Treatment Facility.

3 Feb 2010

Mentor Capital's Cancer Immunotherapy Index: First funding tranche to extend investment closes

Mentor Capital, Inc.'s first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.

2 Feb 2010

Docking algorithm EADock allows successful design of new inhibitors for anti-cancer target

Many human tumors express indoleamine 2,3-dioxygenase (IDO), an enzyme which mediates an immune-escape in several cancer types. Researchers in the Molecular Modeling group at the SIB Swiss Institute of Bioinformatics and Dr. Beno-t J. Van den Eynde's group at the Ludwig Institute for Cancer Research Ltd (LICR) Brussels Branch developed an approach for creating new IDO inhibitors by computer-assisted structure-based drug design. The study was presented in the January 2010 online issue of the Journal of Medicinal Chemistry.

30 Jan 2010

Global market for oncology drugs is forecast to reach $80 billion by 2050

New Medicine's Oncology KnowledgeBASE (nm/OK) residing at http://nmok.net became available on the Internet 10 years ago and, since then, the oncology field has evolved into one of the most challenging, complex and promising drug development sectors, both in terms of its potential contribution to medicine and to its market opportunities.

29 Jan 2010

Juvaris BioTherapeutics completes second close on its Series B equity financing

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed a second close on its Series B equity financing of up to $25 million. The additional equity investment came from an undisclosed strategic corporate investor who joins SV Life Sciences and Kleiner Perkins Caufield & Byers in the round.

27 Jan 2010

Mayo Clinic achieves new levels of excellence in service to humanity

Mayo Clinic announced today that it raised $1.35 billion in its first comprehensive fundraising campaign, surpassing the goal of $1.25 billion.

27 Jan 2010

Prometheus Laboratories executes commercialization agreement with Novartis

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a commercialization agreement with Novartis under which Prometheus acquired exclusive rights to distribute, promote and sell PROLEUKIN® (aldesleukin) in the United States.

27 Jan 2010

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell vaccines targeting house dust mite and cat allergies. With the start of these studies, and the ongoing trial of Circassia's ragweed allergy (hay fever) T-cell vaccine, the company now has three clinical development programmes in phase II.

19 Jan 2010

Immunotherapy News and Research

Latest Immunotherapy News and Research

TopoTarget pays Celldex Therapeutics $3M sublicense income over Belinostat co-development agreement

Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency

People can take simple steps to minimize risk of exposure to allergens during gardening, AAAAI

Ragweed pollen allergy: SLIT safe and effective alternative to injections

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

NewLink Genetics receives FDA SPA approval for HyperAcute immunotherapy Phase 3 pancreatic cancer trial

Intellect Neurosciences: Several significant stakeholders commit funds

LRF's 2009 Mantle Cell Lymphoma Consortium report published

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Advaxi to receive fund from CRUK for clinical trial of ADXS11-001

Market Media Connect retained as Northwest Biotherapeutics' communications agency of record

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

HST Global plans to develop new Clinical Treatment Facility in Ecuador

Mentor Capital's Cancer Immunotherapy Index: First funding tranche to extend investment closes

Docking algorithm EADock allows successful design of new inhibitors for anti-cancer target

Global market for oncology drugs is forecast to reach $80 billion by 2050

Juvaris BioTherapeutics completes second close on its Series B equity financing

Mayo Clinic achieves new levels of excellence in service to humanity

Prometheus Laboratories executes commercialization agreement with Novartis

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in